CLINICAL_TRIALS
trial_result
· 2022-06-09
Clinical Trial Update: Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis [Phase 2]
Summary
Phase 2 study of Kyowa Kirin's anti-OX40 monoclonal antibody KHK4083 in moderate-to-severe atopic dermatitis completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kyowa Kirin, Inc. | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2022-06-09